Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules
The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug
PfizerForAll works within the existing healthcare system and through a growing network of partners to simplify access via established channels and to close gaps in care
Honeywell Quality Management Review helps manufacturers boost efficiency and quality compliance
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
The company recorded sales of Rs. 1,129 crore for the fiscal year ended June 30, 2024,
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Subscribe To Our Newsletter & Stay Updated
